03.08.2020: Free Application Note - NaV1.5-ΔKPQ late INa current properties and pharmacology
Activation and inactivation of peak currents of NaV1.5-ΔKPQ
What you will learn:
- Peak and late INa could be reliably recorded from NaV1.5-ΔKPQ expressing HEK cells without pharmacological enhancement; which could potentially interact with test compounds.
- Late INa from NaV1.5-ΔKPQ was more potently inhibited by ranolazine and mexiletine than peak NaV1.5-ΔKPQ or WT peak currents.
- Using the SyncroPatch 384i automated patch clamp system in combination with the NaV1.5-ΔKPQ cell line provided a reliable high throughput CiPA-compliant cardiac safety screening assay without the need for openers such as ATX-II.